FindTrial
Sign In

A randomized control trial of Azithromycin on immune modulation in patients with sepsis

A randomized control trial of Azithromycin on immune modulation in patients with sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063417
Enrollment
Unknown
Registered
2022-09-06
Start date
2022-08-23
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

experimental group:azithromycin
control group:levofloxacin

Sponsors

Beijing Friendship Hospital, Capital Medical University, Beijing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: From August 2022 to August 2023, patients aged >= 18 years and <= 75 years old who met the diagnosis of sepsis were continuously admitted to the Emergency Department of Beijing Friendship Hospital affiliated to Capital Medical University.

Exclusion criteria

Exclusion criteria: 1. Advanced tumor; 2. Terminal stage of various diseases, connective tissue disease and immune disease, cerebrovascular disease and long-term bedridden, vegetative state and dementia.

Design outcomes

Primary

MeasureTime frame
28-day mortality rate;—

Secondary

MeasureTime frame
biomarker;—

Countries

China

Contacts

Public ContactXie Miaorong

Beijing Friendship Hospital, Capital Medical University

xiemiao27@126.com+86 13701103422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026